What is PTC Therapeutics's revenue?

PTC Therapeutics (PTCT) generated $827.1M in revenue over the trailing twelve months, down 53.3% year over year.

Is PTC Therapeutics profitable?

PTC Therapeutics reported $814.8M in net income over the trailing twelve months, a 42.3% net margin.

What are PTC Therapeutics's profit margins?

Gross margin is 96.0% and operating margin is 1.6%, with a 42.3% net margin.

What is PTC Therapeutics's earnings per share?

PTC Therapeutics's diluted EPS over the trailing twelve months is $9.38.

Where does PTC Therapeutics's income statement data come from?

Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

PTC Therapeutics PTCT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$1.73B+115%	$806.78M-14.0%	$937.82M+34.2%	$698.8M+29.7%
Research and development	$455.25M-14.8%	$534.48M-19.8%	$666.56M+2.3%	$651.5M+20.5%
Selling, general and administrative	$347.14M+15.4%	$300.91M-9.5%	$332.54M+2.0%	$326M+14.1%
Depreciation and amortization	$24.74M-59.3%	$60.74M-72.7%	$222.64M+91.0%	$116.55M+113%
Other operating expenses	$863.72M-22.1%	$1.11B-19.5%	$1.38B+20.2%	$1.15B+25.5%
Total operating expenses	$863.72M-22.1%	$1.11B-19.5%	$1.38B+20.2%	$1.15B+25.5%
Operating income	$938.28M+410%	-$302.57M+32.1%	-$445.32M+0.5%	-$447.41M-19.5%
Operating margin	54.2%+91.7pp	-37.5%+10.0pp	-47.5%+16.5pp	-64%+5.5pp
Interest expense	-$152.23M+8.8%	-$166.99M-29.3%	-$129.18M-42.2%	-$90.87M-5.6%
Other income (expense), net	-$18.09M-376%	$6.54M-35.4%	$10.13M—	——
Income before income taxes	——	-$363.12M+47.8%	-$696.11M-18.5%	-$587.49M-13.3%
Income tax expense	——	——	-$69.51M-144%	-$28.47M-612%
Net income	——	-$363.3M+42.0%	-$626.6M-12.1%	-$559.02M-6.7%
Diluted earnings per share	——	-$4.73+43.4%	-$8.36-7.2%	-$7.80-5.1%
Basic earnings per share	——	-$4.73+43.4%	-$8.36-7.2%	-$7.80-5.1%
Weighted-average shares, diluted	340M+10.7%	307M+2.8%	298.7M+4.4%	286M+1.5%
Weighted-average shares, basic	314.3M+2.4%	307M+2.8%	298.7M+4.4%	286M+1.5%
Cost Of Goods And Service Excluding Amortization Of Intangible Assets	$47.01M-18.1%	$57.4M-12.4%	$65.49M—	——
Gain Loss On Disposition And Impairment Of Tangible Assets	$9.63M—	——	——	——
Interest Income (Expense), Nonoperating	-$152.23M+8.8%	-$166.99M-29.3%	-$129.18M-42.2%	-$90.87M-5.6%
Amortization of capitalized software and acquired intangible assets	$24.74M-59.3%	$60.74M-72.7%	$222.64M+91.0%	$116.55M+113%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1	——	$4.48M-96.5%	$127.7M—	——
Gain Loss On Priority Review Voucher	——	$99.9M—	——	——
Other income, net (Note 6)	-$18.09M-376%	$6.54M-35.4%	$10.13M—	——
Revenue From Contract With Customer Excluding Assessed Tax	$1.73B+115%	$806.78M-14.0%	$937.82M+34.2%	$698.8M+29.7%
EBIT	$938.28M+410%	-$302.57M+32.1%	-$445.32M+0.5%	-$447.41M-19.5%
EBITDA	$977.1M+531%	-$226.91M-8.7%	-$208.73M+34.5%	-$318.58M-2.7%
EBITDA	$977.1M+531%	-$226.91M-8.7%	-$208.73M+34.5%	-$318.58M-2.7%
EBITDA margin	56.5%+84.6pp	-28.1%-5.9pp	-22.3%+23.3pp	-45.6%+12.0pp
EBIT	$938.28M+410%	-$302.57M+32.1%	-$445.32M+0.5%	-$447.41M-19.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about PTC Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's revenue?: PTC Therapeutics (PTCT) generated $827.1M in revenue over the trailing twelve months, down 53.3% year over year.
Is PTC Therapeutics profitable?: PTC Therapeutics reported $814.8M in net income over the trailing twelve months, a 42.3% net margin.
What are PTC Therapeutics's profit margins?: Gross margin is 96.0% and operating margin is 1.6%, with a 42.3% net margin.
What is PTC Therapeutics's earnings per share?: PTC Therapeutics's diluted EPS over the trailing twelve months is $9.38.
Where does PTC Therapeutics's income statement data come from?: Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.